Amyloid Beta and the Brain: Where Are We Now? by Fedele, Ernesto et al.
Volume 5 • Issue 2 • 1000e147
J Biomol Res Ther
ISSN: 2167-7956 JBMRT, an open access journal 
Open AccessEditorial









ular Research & Therapeutics
ISSN: 2167-7956
Fedele et al., J Biomol Res Ther 2016, 5:2
http://dx.doi.org/10.4172/2167-7956.1000e147
Alzheimer’s disease (AD) is certainly the most devastating and 
common form of dementia afflicting more than 40 million people 
worldwide today, with an expected escalation up to 130 million 
by 2050. The early sign of dementia is represented by the difficulty 
in remembering recent events but more symptoms emerge as AD 
inexorably progresses, including confusion, disorientation, severe 
memory loss and cognitive alterations, mood and behavioural changes, 
difficulties in reading, writing, speaking, swallowing and walking. 
These increasing disabilities dramatically affect the daily life of patients 
but also of their relatives, and have a highly relevant socioeconomic 
impact, taking into account direct, indirect and intangible costs [1].
Certainly, in the last 30 years a milestone of AD research has 
been the discovery of the amyloid β peptide (Aβ) that, since then, 
has been considered the main cause of the pathology. Thus, the 
“amyloid hypothesis” soon became the prevailing theoretical model 
of AD pathophysiology that is still driving the development of 
pharmacological treatments.
Aβ peptides originate from the cleavage of a transmembrane 
precursor protein called APP (Amyloid Precursor Protein) that is first 
processed by a β-secretase (BACE, beta-site APP-cleaving enzyme) 
and then by a γ-secretase. Among the different fragments produced by 
this processing, Aβ1−42 is more self-aggregating than Aβ1−40 that, on the 
other hand, has been shown to prevent Aβ1−42 deposition [2]. 
At present, it is quite clear that neurotoxicity is not initiated by 
aggregation of amyloid peptides into senile plaques, as originally 
thought, but rather by formation of soluble β-amyloid dimers/
oligomers that have been shown to impair long-term potentiation 
(LTP), to enhance long-term depression (LTD), to alter synaptic 
structures and, consequently, to deteriorate memory [3]. 
Indeed, it has been hypothesized that Aβ plaques could represent 
a defence mechanism to sequester soluble synaptotoxic Aβ species [4]. 
In line with this view, amyloid plaque cores, directly isolated from AD 
patients, are not able to affect LTP that, on the contrary, is impaired 
by soluble oligomers released from plaques using strong denaturants 
[3]. Interestingly, a recent study has found that the oligomer/plaque 
ratio was significantly higher in mildly demented patients than in non-
demented control subjects with the same amyloid plaque burden [5]. 
Although Aβ1−40 and Aβ1−42 are the most common forms, 
increasing evidence demonstrate that there are far more peptide 
species that accumulate in AD brains (e.g. Aβ1−37,38,43,56, AβpE), which 
can be modified over time and that could play a pathogenic role in 
the development of the disease [6]. To further complicate Aβ peptide 
heterogeneity, it has been recently shown that novel, N-terminally 
extended Aβ− containing monomers (NTE-Aβ), produced in cells 
expressing mutant human APP, can impair hippocampal LTP in vivo 
[7]. These fragments are distinct from classical Aβ1−40/42 oligomers and, 
unexpectedly, their levels increase upon inhibition of β-secretase, 
suggesting that they could originate from a protease cleavage different 
from that of BACE. 
As for the mechanisms through which Aβ can exert its toxic 
effects, several lines of evidence have identified a plethora of proteins 
which monomers, dimers and oligomers can bind to, such as α7-
nAChR, NMDA receptor, RAGE, insulin receptor, PrPc and others 
[8,9]. However, the role of many of these proteins is still a matter of 
controversy and the use of different, often poorly characterized, Aβ 
oligomers to target them in different in vitro or in vivo models has led 
to a rather confusing scenario. 
In any case, although we have certainly increased our knowledge 
on APP processing and Aβ toxicity, it has become evident that the 
amyloid hypothesis is not sufficient to explain the pathophysiology of 
AD, the living proof being the almost complete failure of clinical trials 
aimed at reducing the brain levels of this peptide in AD patients. 
But should we really aim at clearing Aβ from the brain? 
Over the last decade or so, a growing body of data has provided 
incontrovertible evidence for a key role of this peptide in the biological 
functions of the brain. 
First of all, it has to be borne in mind that Aβ is present not 
only in the brain of AD patients but also in healthy individuals and 
it is produced physiologically at low (picomolar) concentrations 
throughout lifetime.
One of the first evidence suggesting that Aβ could participate in 
normal central functions came from studies on APP knockout mice, 
which showed memory deficits in the conditioned avoidance test and 
in the Morris water maze. In addition, hippocampal LTP in these 
animals was significantly impaired and was associated with abnormal 
neuronal morphology [10,11]. Similar results were successively 
obtained in BACE KO mice [12]. However, the decisive evidence 
of Aβ  involvement in memory formation has been provided by the 
finding that clearing the peptide from the hippocampus, using selective 
antibodies, resulted in the impairment of LTP that led to contextual 
fear and reference memory deficits; moreover, all these antibody-
induced alterations were indeed rescued by the addition of exogenous 
Aβ1−42 [13]. In this context, we have recently demonstrated that APP 
expression and Aβ production are controlled by the second messenger 
cAMP through activation of PKA, and that endogenous Aβ is necessary 
for cAMP-mediated expression of LTP [14,15].
Also in this case, Aβ classical fragments do not seem the only 
species able to modulate memory formation. In fact, it has been recently 
reported that a monomeric N-terminal Aβ1−15 fragment, present in the 
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CSF of healthy individuals as well as of AD patients, is able to potently 
enhance hippocampal LTP (50 fM) and to improve memory in the 
contextual fear conditioning paradigm [16]. Intriguingly enough, 
the hippocampal LTP impairment caused by high concentrations of 
exogenous Aβ1−42 (slices from wild type mice) or by endogenous Aβ 
(slices from APPSWE transgenic mice) was rescued by pre-treatment 
with Aβ1−15.
Apart from memory formation, Aβ has been shown to play also 
critical roles in neuronal survival, since its reduction by β- or γ-secretase 
inhibitors, as well as its immunodepletion, caused neuronal death in 
cortical cultures that could be prevented by addition of physiological 
concentrations of Aβ [17]. At variance with this result, however, APP 
KO mice showed marked reactive gliosis, loss of presynaptic and 
dendritic markers, but not neuronal death [10], probably because of 
compensatory mechanisms operating during development.
It has also been proposed that Aβ is involved in the physiological 
control of neuronal activity by depressing synaptic functions through 
a negative feedback mechanism, once increased synaptic activity 
enhances the production of Aβ itself [18].
Finally, up regulation of Aβ production could also represent a 
protective cellular response to oxidative stress, as it can sequester metal 
ions and can act as an antioxidant scavenging free radicals [19].
Thus, although an enormous progress has been done in elucidating 
the various pathological aspects of APP processing and Aβ formation, 
we have just commenced to unravel the physiological roles of this 
peptide in the brain. Such aspect is of fundamental importance if 
we intend to understand Alzheimer’s disease and develop successful 
therapeutic interventions.
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